C4 Therapeutics is harnessing the innate power of the body to control the quality of proteins within cells. Our approach uses drugs to target disease-causing proteins for destruction. This breakthrough technology offers many advantages for the treatment of cancer and other diseases, while avoiding traditional drug resistance.
C4 Therapeutics Announces the Addition of Leading Researchers to SAB
CAMBRIDGE, Mass. July 27, 2017 – C4 Therapeutics (C4T) today announced the appointment of Scott Armstrong, M.D, Ph.D., and Ross Levine, MD, to the Company's Scientific Advisory Board (SAB).
“C4T has established a scientific advisory board that brings together leading scientists and physicians representing a range of disciplines,” said Andrew (Andy) Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. "We are delighted to have Scott and Ross, both expert physician-scientists in the hematology-oncology field, join our team to advise us as we advance our technology and deliver on our key research objectives and operational goals of the Company.” read more
C4 Therapeutics and Calico Enter Strategic Partnership
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif – March 23, 2017 – C4 Therapeutics (C4T) and Calico today announced a five-year collaboration to discover, develop, and commercialize therapies for treating diseases of aging, including cancer.
“We are thrilled to have Calico as partners in pioneering novel therapeutics based on targeted protein degradation,” said Andrew Phillips, President and Chief Scientific Officer of C4 Therapeutics. “Calico's leadership team has a long record of innovation and our combined efforts are aimed at bringing forward new options for patients affected by devastating diseases such as cancer.” read more...
C4 Therapeutics Announces World-Class Scientific Advisory Board
Cambridge, MA. – November 17, 2016 – C4 Therapeutics (C4T) today announced Ken Anderson, M.D., Nathanael Gray, Ph. D., Christopher Kirk, Ph. D. and Eric Fischer, Ph. D as the members of its Scientific Advisory Board (SAB).
“We are thrilled to have Ken, Nathanael, Chris, and Eric play an important role as our advisors at C4T,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Their world-renowned expertise in clinical oncology, drug discovery and development, and the basic-science of the ubiquitin-proteasome system will be invaluable as we both advance drug candidates toward the clinic and develop new tools and technologies that keep C4T at the cutting edge.” read more...
What We Do